TOKYO (Reuters) – Japanese biotech company AnGes Inc said on Tuesday it had initiated a phase 2/3 clinical trial of its DNA-based COVID-19 vaccine candidate.
The study is taking place at eight facilities in eastern and western Japan involving 500 test subjects, the company said in a statement.
(Reporting by Rocky Swift; Editing by Kim Coghill)
